- Atlas
- Medicine & Health
- Autoimmunity
Autoimmunity
Autoimmunity is the study of how the immune system can turn against the body it belongs to.
12 frameworks, from 1899 to today · Immunology · Medicine & Health
- Horror Autotoxicus 1899-1955
- Autoantibody-Based Autoimmune Disease Recognition 1904-Present
- Immune tolerance 1953-1985
- Clonal selection 1957-Present
- Antigen-Specific Tolerance Induction 1970-Present
- Human leukocyte antigen 1973-Present
- Hygiene and Old Friends Hypotheses 1989-Present
- Immune checkpoint 1995-Present
- Regulatory T cell 1995-Present
- Cytokine and Biologic Pathway Targeting 1998-Present
- Microbiome-Immune Regulation Framework 2005-Present
- Molecular Subtyping and Precision Medicine in Autoimmunity 2005-Present
Overview
Autoimmunity is the study of how the immune system can turn against the body it belongs to. Its central puzzle is a paradox: the same machinery that recognizes and destroys invading microbes can, under some circumstances, recognize and destroy a person's own tissues1. What is at stake is not only a set of diseases—type 1 diabetes, rheumatoid arthritis, multiple sclerosis, lupus, and many others—but a fundamental question about how the immune system distinguishes self from non-self1. The history of autoimmunity is the history of how immunologists came to accept that such self-attack is real, how they explained it, and how they learned to measure and treat it.
Horror Autotoxicus and the Denial of Self-Attack
In the late nineteenth and early twentieth centuries, immunology was dominated by the study of humoral immunity—the protective action of antibodies in blood serum. The German bacteriologist Paul Ehrlich, working in the 1890s and early 1900s, proposed that the body possesses a natural aversion to attacking its own tissues. He called this principle horror autotoxicus—literally "fear of self-poisoning."12 Ehrlich reasoned that if antibodies could be raised against the body's own cells, the result would be catastrophic, and he believed the organism had evolved mechanisms to prevent it. This idea became a foundational assumption: the immune system was understood as a defense against foreign invaders, and self-tolerance was assumed to be absolute1.
The first serious challenge came from the work of the Russian-born immunologist Élie Metchnikoff, who had discovered phagocytosis in the 1880s, and from later clinicians who observed that animals injected with their own tissues could sometimes produce antibodies against them. In 1904, the French immunologist Jules Bordet and his colleague Octave Gengou demonstrated that antibodies could be raised against red blood cells of another species, and similar experiments with self-tissues followed. But these findings were often dismissed as laboratory artifacts or as consequences of tissue damage rather than genuine autoimmune reactions. The horror autotoxicus framework held sway because it fit the dominant view of immunity as a purely defensive, outward-facing system1.
Autoantibody Diagnostics and the Recognition of Autoimmune Disease
The decisive break came from clinical observation. In 1904, the German physician Julius Donath and the Austrian immunologist Karl Landsteiner described paroxysmal cold hemoglobinuria, a condition in which exposure to cold caused red blood cells to burst. They showed that a factor in the patient's serum—an antibody—bound to the patient's own red cells in the cold and triggered their destruction. This was one of the first clear demonstrations that an antibody could target self-tissue and cause disease.
A more systematic recognition followed in the 1940s and 1950s. In 1945, the American hematologist Robert Coombs and his colleagues developed the antiglobulin test (now called the Coombs test), which detected antibodies bound to red blood cells. This made it possible to diagnose autoimmune hemolytic anemia—a condition in which the body destroys its own red blood cells. Around the same time, the American physician Philip Hench and the biochemist Edward Kendall at the Mayo Clinic observed that cortisone, a steroid hormone, dramatically suppressed inflammation in rheumatoid arthritis. This suggested that the immune system was actively involved in the disease, though the precise mechanism remained unclear.
The 1950s brought a wave of autoantibody discoveries. In 1957, the British immunologist Deborah Doniach and her colleagues described antibodies against thyroid tissue in patients with Hashimoto's thyroiditis, a chronic inflammatory disease of the thyroid gland. In the same period, antibodies against cell nuclei (antinuclear antibodies) were found in patients with systemic lupus erythematosus (SLE), a disease in which the immune system attacks multiple organs. These findings established that autoantibodies were not rare curiosities but common features of a class of diseases. The term "autoimmune disease" entered clinical use, and the horror autotoxicus doctrine was effectively overturned—though the question of how self-tolerance normally works remained open.
Acquired Immunological Tolerance and the Clonal Selection Theory
The theoretical foundation for understanding self-tolerance came from two related developments in the mid-twentieth century. The first was the demonstration of acquired immunological tolerance. In 1953, the British immunologist Peter Medawar and his colleagues showed that mice injected with foreign cells before birth or shortly after birth would accept skin grafts from the same donor strain later in life. This phenomenon, called neonatal tolerance, proved that the immune system could be taught to accept foreign tissue if exposed to it early enough. Medawar's work, building on earlier observations by the Australian immunologist Frank Macfarlane Burnet, suggested that tolerance is not innate but acquired through exposure during development.
The second development was the clonal selection theory, proposed by Burnet in 19573. Burnet argued that each lymphocyte (a type of white blood cell) carries a unique receptor for a specific antigen, and that when an antigen binds to that receptor, the lymphocyte is selected to proliferate and produce antibodies or effector cells3. Crucially, Burnet proposed that lymphocytes with receptors that recognize self-antigens are eliminated during development—a process he called "clonal deletion."14 This provided a mechanism for self-tolerance: the immune system learns to ignore self by destroying self-reactive clones before they can mature1. The clonal selection theory became the central framework of modern immunology and offered a clear explanation for why autoimmunity is the exception rather than the rule.
The MHC-HLA Genetic Association Framework
While Burnet's theory explained how self-tolerance might be established, it did not explain why some people develop autoimmune diseases and others do not. The answer began to emerge from genetics. In the 1960s and 1970s, immunologists discovered the major histocompatibility complex (MHC)—a cluster of genes that encode proteins on the surface of cells that present antigens to T cells. In humans, this is called the human leukocyte antigen (HLA) system5. The MHC proteins are highly variable between individuals, and this variability determines which antigens are presented to the immune system6.
In 1973, the British immunologist John Dausset and the American immunologist Baruj Benacerraf, along with the Swiss immunologist Jean Dausset (working independently), showed that certain HLA types were strongly associated with specific autoimmune diseases. For example, HLA-B27 was found to be linked to ankylosing spondylitis, a chronic inflammatory arthritis of the spine1. Later work in the 1980s and 1990s identified HLA-DR4 and HLA-DR3 associations with rheumatoid arthritis and type 1 diabetes, respectively. The MHC-HLA framework provided a genetic explanation for susceptibility: certain HLA molecules may present self-antigens in a way that activates self-reactive T cells, or may fail to present them in a way that induces tolerance. This framework remains central to understanding the genetic basis of autoimmunity.
Regulatory T Cells and the Active Suppression of Self-Reactivity
The clonal selection theory implied that self-reactive lymphocytes are deleted during development1. But in the 1980s and 1990s, immunologists discovered that self-reactive T cells are not always eliminated; some persist in the periphery and must be actively controlled. The key discovery was the regulatory T cell (Treg), a subset of T cells that suppresses the activity of other immune cells7. In 1995, the Japanese immunologist Shimon Sakaguchi and his colleagues showed that a specific subset of T cells—those expressing the marker CD25—could prevent autoimmune disease in mice. When these cells were removed, the mice developed spontaneous autoimmune conditions. This demonstrated that self-tolerance is not merely a passive process of deletion but an active one of suppression1.
The regulatory T cell theory was further solidified by the discovery of the transcription factor Foxp3, which is required for Treg development and function8. Mutations in the Foxp3 gene were found to cause a severe autoimmune syndrome in humans called IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked). This provided a direct link between Treg dysfunction and autoimmunity. The Treg framework shifted the understanding of autoimmunity from a simple failure of deletion to a more complex failure of active regulation.
The Hygiene and Old Friends Hypotheses
Why do autoimmune diseases appear more common in wealthy, urbanized societies? In 1989, the British epidemiologist David Strachan proposed the hygiene hypothesis, suggesting that reduced exposure to infections in early childhood—due to improved sanitation and smaller family sizes—leads to a higher risk of allergic and autoimmune diseases. The idea was that the immune system needs to be "educated" by microbes to develop proper regulation.
This hypothesis was later refined into the "old friends" hypothesis by the British immunologist Graham Rook in the 2000s. Rook argued that it is not infections per se that matter, but exposure to harmless environmental microbes—particularly those that co-evolved with humans, such as certain bacteria and helminths (parasitic worms). These "old friends" help train the immune system to tolerate self and harmless antigens. The hygiene and old friends hypotheses provided an ecological and evolutionary perspective on autoimmunity, linking changes in human lifestyle to the rise in autoimmune diseases. They also motivated research into the microbiome—the community of microbes living in and on the body—as a regulator of immune tolerance.
The Microbiome-Immune Regulation Framework
The microbiome emerged as a major focus in the 2000s and 2010s, driven by advances in DNA sequencing that allowed researchers to catalog the bacteria, viruses, and fungi living in the gut, skin, and other sites. Studies in mice showed that germ-free animals—raised in sterile conditions—have altered immune development and are more susceptible to autoimmune conditions. In humans, changes in the gut microbiome were associated with diseases such as inflammatory bowel disease, type 1 diabetes, and multiple sclerosis.
The microbiome-immune regulation framework proposes that the composition of the microbiota influences the balance between pro-inflammatory and regulatory immune responses. For example, certain gut bacteria produce short-chain fatty acids that promote Treg development, while others may trigger inflammatory pathways. This framework connects the hygiene hypothesis to molecular mechanisms and has opened new avenues for therapy, such as fecal microbiota transplantation and probiotic interventions, though clinical evidence for their efficacy in autoimmunity remains limited.
The Immune Checkpoint Framework and Cytokine Targeting
The late twentieth and early twenty-first centuries saw the rise of targeted therapies that manipulate specific immune pathways. The immune checkpoint framework emerged from the discovery of molecules that either activate or inhibit T cells. In the 1990s, the American immunologist James Allison and the Japanese immunologist Tasuku Honjo independently identified CTLA-4 and PD-1, respectively, as inhibitory receptors on T cells. Blocking these checkpoints—using antibodies such as ipilimumab (anti-CTLA-4) and pembrolizumab (anti-PD-1)—releases the brakes on the immune system and has proven remarkably effective against some cancers. But this same strategy can trigger autoimmune side effects, demonstrating that checkpoints are critical for maintaining self-tolerance.
Conversely, the cytokine and biologic pathway targeting framework focuses on blocking specific inflammatory molecules. Tumor necrosis factor (TNF) was identified in the 1970s and 1980s as a key mediator of inflammation. In the late 1990s, anti-TNF therapies (such as infliximab and etanercept) were approved for rheumatoid arthritis and Crohn's disease, revolutionizing treatment. Later, therapies targeting interleukins (such as IL-6 and IL-17) and B cells (such as rituximab, which depletes B cells) were developed. These biologics demonstrated that autoimmunity could be treated by interrupting specific molecular pathways, and they provided proof that autoantibodies and inflammatory cytokines are directly pathogenic in many diseases.
Antigen-Specific Tolerance Induction
While broad immunosuppression and cytokine blockade are effective, they carry risks of infection and cancer. A long-standing goal has been antigen-specific tolerance induction—teaching the immune system to tolerate a specific self-antigen without suppressing the rest of the immune response. Early attempts in the 1970s and 1980s used oral administration of antigens (oral tolerance) to suppress autoimmune responses in animal models. For example, feeding mice with myelin basic protein—a component of the nerve sheath—could prevent experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis.
More recent approaches include the use of nanoparticles coated with antigens to induce Tregs, and the engineering of tolerogenic dendritic cells. While these strategies have shown promise in animal models, translating them to human autoimmune diseases has proven difficult. Clinical trials of oral tolerance in multiple sclerosis and rheumatoid arthritis have had mixed results, and antigen-specific tolerance remains an active area of research rather than a standard therapy.
Molecular Subtyping and Heterogeneity
As the understanding of autoimmunity deepened, it became clear that diseases like lupus or rheumatoid arthritis are not single entities but collections of subtypes with different molecular mechanisms. The molecular subtyping and heterogeneity framework emerged from genomics and transcriptomics in the 2000s and 2010s. Researchers began to classify patients based on gene expression profiles, autoantibody patterns, and cytokine signatures. For example, in lupus, some patients have high levels of type I interferon—a class of antiviral proteins—while others do not. This heterogeneity explains why some patients respond to certain therapies and others do not.
Molecular subtyping has led to the concept of precision medicine in autoimmunity: tailoring treatment to the specific molecular pathway driving a patient's disease. It has also revealed that autoimmune diseases share some mechanisms with immunodeficiency and cancer, blurring the boundaries between disease categories.
The Present: Integrated Approaches and Open Questions
Today, autoimmunity research integrates genetics, immunology, microbiology, and clinical medicine. The main approaches in use descend directly from the history above: clonal selection and tolerance theory provide the conceptual foundation; MHC-HLA typing and autoantibody diagnostics are standard clinical tools; regulatory T cell biology informs new therapies; the microbiome is a target for intervention; and biologic drugs targeting cytokines and checkpoints are mainstays of treatment. Antigen-specific tolerance and molecular subtyping represent the frontier, aiming for therapies that are both precise and durable.
Open questions remain. Why does self-tolerance fail in some people and not others? How do environmental factors—infections, diet, stress—interact with genetic susceptibility? Can we induce lasting tolerance without compromising defense against infection? And how can the heterogeneity of autoimmune diseases be harnessed to deliver the right treatment to the right patient? These questions continue to drive the field, which has come a long way from the doctrine of horror autotoxicus but still faces the fundamental puzzle of how the immune system decides whom to attack.
References
- Autoimmunity (introduction, History, Immunological tolerance, Genetic factors), Wikipedia
- Paul Ehrlich (First work on immunity), Wikipedia
- Clonal selection, Wikipedia
- Immune tolerance (Historical background), Wikipedia
- Human leukocyte antigen, Wikipedia
- Major histocompatibility complex, Wikipedia
- Regulatory T cell, Wikipedia
- FOXP3, Wikipedia
The frameworks of Autoimmunity
Each framework is a way of working the field has used: when it held, and the question it answers.
- 1899-1955
- 1904-Present
Autoantibody-Based Autoimmune Disease Recognition
Can antibodies target the body's own cells?
- 1953-1985
- 1957-Present
Clonal selection
How does the immune system choose which cells to expand?
- 1970-Present
Antigen-Specific Tolerance Induction
Can tolerance to a specific antigen be induced?
- 1973-Present
Human leukocyte antigen
Why do some people get autoimmune disease and others not?
- 1989-Present
Hygiene and Old Friends Hypotheses
Why are autoimmune diseases more common in rich societies?
- 1995-Present
- 1995-Present
- 1998-Present
Cytokine and Biologic Pathway Targeting
Which immune signaling molecules drive autoimmune damage?
- 2005-Present
Microbiome-Immune Regulation Framework
How do gut microbes shape immune tolerance?
- 2005-Present
Molecular Subtyping and Precision Medicine in Autoimmunity
Can autoimmune patients be grouped by molecular profile?
How the ideas connect
Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.
Autoantibody-Based Autoimmune Disease Recognition reacted against Horror Autotoxicus
Donath and Landsteiner's demonstration that a patient's own serum antibody could lyse his red cells in paroxysmal cold hemoglobinuria directly contradicted Ehrlich's horror autotoxicus, and the later autoantibody disease work defined itself against that prohibition.
Carried by Julius Donath; Karl Landsteiner.
Clonal selection influenced by Immune tolerance
Medawar's demonstration of acquired neonatal tolerance supplied Burnet with the empirical phenomenon his clonal selection theory explained through clonal deletion of self-reactive lymphocytes.
Carried by Peter Medawar; Frank Macfarlane Burnet.
Regulatory T cell influenced by Clonal selection
Sakaguchi's demonstration that CD25+ T cells actively suppress self-reactivity showed that clonal deletion alone could not account for tolerance, and the regulatory T cell framework was built on that gap.
Carried by Shimon Sakaguchi.
Immune tolerance influenced by Autoantibody-Based Autoimmune Disease Recognition
The recognition that autoantibodies could attack self-tissue posed the question of why this does not normally happen, which Medawar's neonatal tolerance experiments and Burnet's theorizing addressed by showing tolerance is acquired.
Carried by Peter Medawar; Frank Macfarlane Burnet.
Regulatory T cell influenced by Immune tolerance
The acquired-tolerance tradition framed tolerance as something the immune system learns; the regulatory T cell work recast that learning as active suppression by a dedicated cell subset rather than deletion.
Carried by Shimon Sakaguchi.
Antigen-Specific Tolerance Induction influenced by Clonal selection
Clonal selection's picture of antigen-specific lymphocyte clones gave later workers the conceptual target for inducing tolerance to defined antigens rather than whole tissues.
Human leukocyte antigen influenced by Clonal selection
Clonal selection made antigen presentation to specific lymphocyte clones central, and the HLA association work explained disease susceptibility through which self-antigens MHC molecules present to those clones.
Carried by Baruj Benacerraf; John Dausset.
Molecular Subtyping and Precision Medicine in Autoimmunity influenced by Human leukocyte antigen
HLA typing established that autoimmune disease susceptibility is genetically heterogeneous, providing the template for later molecular subtyping of patients into distinct disease endotypes.
Microbiome-Immune Regulation Framework influenced by Hygiene and Old Friends Hypotheses
The hygiene and old friends hypotheses proposed that microbial exposure shapes immune regulation; the microbiome framework gave that claim a concrete mechanistic object by sequencing commensal communities.
Carried by David Strachan.
Microbiome-Immune Regulation Framework influenced by Regulatory T cell
Regulatory T cell biology supplied the mechanism by which commensal microbes were proposed to maintain tolerance, so microbiome-immune work measured Treg induction by gut bacteria.
Molecular Subtyping and Precision Medicine in Autoimmunity influenced by Cytokine and Biologic Pathway Targeting
Biologic pathway targeting showed that patients with the same clinical diagnosis respond differently to cytokine blockade, motivating molecular subtyping to match patients to pathways.
Beyond the field
Where Autoimmunity's ideas came from in other fields, and what they led to there: the strongest 12 of 86 links.
Horror Autotoxicus influenced Immunopathology in Immunology
Ehrlich's horror autotoxicus, the doctrine that the body does not normally turn its immune apparatus against itself, framed the problem that immunopathology addressed when von Pirquet and Schick explained serum sickness as an immune reaction injuring the host. The concept of immune self-damage was formulated against that prohibition.
Carried by Paul Ehrlich; Clemens von Pirquet; Béla Schick.
Horror Autotoxicus provoked Autoimmunity in Clinical Immunology
Ehrlich's horror autotoxicus doctrine held that the organism could not produce antibodies against itself; the modern autoimmunity framework was framed precisely as a rejection of that prohibition, with the rheumatoid-factor and antinuclear-antibody demonstrations as the counter-evidence.
Carried by Paul Ehrlich.
Horror Autotoxicus provoked Autoimmunity in Rheumatology
Ehrlich's doctrine of horror autotoxicus held that the body could not mount an immune attack on itself; the concept of autoimmunity was formulated in direct rejection of that prohibition.
Autoantibody-Based Autoimmune Disease Recognition influenced Multisystem and Overlap Connective Tissue Disease in Rheumatology
Autoantibody-based disease recognition, notably the LE cell phenomenon and antinuclear antibodies, provided the serological markers by which overlap and multisystem connective tissue diseases were defined.
Autoantibody-Based Autoimmune Disease Recognition influenced Autoimmunity in Rheumatology
Detection of autoantibodies, beginning with the Wassermann reaction and later the rheumatoid factor and LE cell phenomena, provided the evidence on which the concept of autoimmunity was founded.
Carried by August von Wassermann; Wassermann reaction (1906).
Immune tolerance influenced Immune Regulation and Tolerance in Immunology
The mid-century immune tolerance work, culminating in Burnet and Fenner's self-marker proposal and Medawar's neonatal tolerance experiments, set the problem that immune regulation and tolerance later took up as its core.
Carried by Frank Macfarlane Burnet; Peter Medawar.
Clonal selection influenced by Immune tolerance in Fundamental Immunology
Burnet's clonal selection theory incorporated acquired immunological tolerance, following Medawar's confirmation of Burnet and Fenner's prediction, by proposing deletion of self-reactive clones. Tolerance became the central test case for the theory.
Carried by Frank Macfarlane Burnet; Peter Medawar.
Clonal selection influenced by Immune tolerance in Host Pathogen Immunology
Clonal selection took up the problem of immune tolerance, explaining it through deletion of self-reactive clones after Medawar's experimental confirmation of tolerance induction. Tolerance is the defining application of the theory.
Carried by Frank Macfarlane Burnet; Peter Medawar.
Antigen-Specific Tolerance Induction grew out of Immune tolerance in Fundamental Immunology
Antigen-specific tolerance induction is the practical branch of immune tolerance research, turning the general phenomenon of acquired tolerance into deliberate protocols for inducing unresponsiveness to defined antigens. It grew directly out of the tolerance framework.
Antigen-Specific Tolerance Induction grew out of Immune tolerance in Host Pathogen Immunology
Antigen-specific tolerance induction derives from the immune tolerance framework, applying its concepts of specific unresponsiveness to designed therapeutic protocols. The later field is a branch of the earlier body of ideas.
Human leukocyte antigen grew out of Histocompatibility in Immunogenetics
Human leukocyte antigen research grew directly out of histocompatibility work, from Gorer's H-2 antigens through the tissue-typing studies of Dausset and Payne. The HLA system was identified as the human histocompatibility system.
Carried by Peter Gorer; Jean Dausset.
Immune checkpoint influenced by Immune tolerance in Fundamental Immunology
Checkpoint blockade is the therapeutic inversion of immune tolerance: the co-inhibitory receptors targeted are the mechanisms of peripheral tolerance, and blocking them deliberately breaks tolerance to tumors. The discovery of CTLA-4 as a negative regulator of T-cell activation supplied the target.
Carried by Craig B. Thompson; James P. Allison.

Autoimmunity is a planet in Nousfarer
Its city has a tower for each of these 12 frameworks. Land, walk in, and climb one concept at a time.
Land on AutoimmunityRelated fields
Fields its ideas are linked to
- Immunology 14 links
- Tumor Immunology 14 links
- Clinical Immunology 10 links
- Immunogenetics 10 links
- Rheumatology 7 links
- Fundamental Immunology 7 links
- Neuroimmunology And Multiple Sclerosis 6 links
- Host Pathogen Immunology 5 links
- Immunotherapy 5 links
- Gastroenterology And Hepatology 1 link
- Nephrology 1 link
- Systems Immunology 1 link